Close Menu

NEW YORK – Chembio Diagnostics said today that is has obtained CE marking for a test that allows simultaneous and discrete detection of antibodies for both active and prior exposure to the Zika, dengue, and chikungunya viruses, an important function for treatment and surveillance.

Medford, New York-based ChemBio said its DPP Zika/Dengue/Chikungunya point-of-care test uses 10 microliters of blood from a fingertip and provides quantitative results in about 15 minutes while operating with the firm's handheld DPP Micro Reader.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.